Jeffrey Cummings, MD Mary S. Easton Center for Alzheimer’s Disease Research Deane F. Johnson Center for Neurotherapeutics David Geffen School of Medicine at UCLA Los Angeles, California, USA
Definition Domains of dementia Epidemiology Causes Pathology of dementias Treatment Evolving directions
Memory impairment Impairment in one other cognitive domain (aphasia, apraxia, agnosia, executive dysfunction) Acquired (not presented throughout life) Disabling (occupational, social) Not present only during delirium Not attributable to a primary psychiatric illness (e.g., major depression, schizophrenia, etc)
Attention (impaired in delirium) Digit span Concentration Memory impairment Orientation (time, place) 3 word learning test with delayed recall
Language Spontaneous speech Naming Comprehension (1,2,3 step command) Repetition Visuospatial skills Copy figures (overlapping pentagons, cube) Draw a clock Executive function Judgment, insight Word list generation (animals named per minute)
Mini-Mental Status Examination (MMSE) Montreal Cognitive Assessment (MoCA) Neuropsychological assessment Dementia is under-recognized Assumed to be normal aging No mental status examination done
Nerve Cell Death Cognitive Impairment Cognitive Impairment Functional Impairment Behavioral Abnormalities
Cognitive Impairment Cognitive Impairment Functional Impairment Behavioral Abnormalities Impairment of: Memory Language Judgment Impairment of: Memory Language Judgment Loss of: Independence Personal Care Relationships Loss of: Independence Personal Care Relationships Agitation Depression Irritability Agitation Depression Irritability Nerve Cell Death
AD is a Progressive, Fatal Illness (Year 0 – all patients were mild (blue; not shown); Comm – community mild (blue), moderate (red), severe (yellow); nh-nursing home; from Neumann PJ et al. Neurology 2001; 57: )
% of Population With Dementia Age
US 5.5 million Alzheimer’s disease patients 2030 – 7.8 million AD patients $148 billion now $1 trillion annually by 2050 Global 35 million AD patients 2-30 – 65 million AD patients
Risk factors Age ApoE-4 genotype Female gender Hypertension, elevated cholesterol Head trauma Protective factors Education Exercise Mental activity
Alzheimer’s disease (55-70% of late-onset dementia) Vascular dementia Parkinson’s disease with dementia and related disorders Dementia with Lewy bodies (DLB) Pathology of Parkinson’s disease and Alzheimer’s disease Frontotemporal dementia (FTD) Misc: trauma, alcohol, B12 deficiency, hypothyroidism, HIV, etc
History Current symptoms Past history and treatments Family history Laboratory tests B12 level Thyroid stimulating hormone (TSH) CBC, electrolytes,, blood sugar, BUN, liver function tests Brain imaging MRI or CT
Dementia established by mental status examination Laboratory Tests Hypothyroidism, B12 deficiency History Trauma, alcoholism, etc Focal neurol signs; + MRI Vascular dementia, focal lesion Parkinsonism Parkinson’s disease, DLB, PD+ None of the above AD, frontotemporal dementia Atypical findings Creutzfeldt-Jakob disease, etc
Memory impairment Impairment in one other cognitive domain (aphasia, apraxia, agnosia, executive dysfunction) Acquired (not presented throughout life) Disabling (occupational, social) Gradually progressive Not present only during delirium Not attributable to a primary psychiatric illness or other cause of dementia
Alzheimer’s disease Brain atrophy Neuritic plaques ▪ Amyloid beta protein Neurofibrillary tangles ▪ Hyperphosphorylated tau protein Loss of nerve cells
Normal Alzheimer’s Disease
Neuritic Plaque Neurofibrillary Tangle
ADNormal Histopathology of Alzheimer’s Disease
Vascular dementia Ischemic white matter lesions Small infarctions in basal ganglia, thalamus, white matter Large infarctions
Dementia with Lewy bodies (DLB) and PD dementia Alpha-synuclein Lewy bodies in brainstem, cortex Limited AD-type pathology in most Frontotemporal dementia Tau protein inclusions TDP-43 protein inclusions Other
Protein Inclusions Tau/TDP-43 Frontotemporal dementia Progressive supranuclear palsy Corticobasal degen. Amyloid AD Dementia with Lewy bodies Alpha-synuclein Parkinson’s disease Dementia with Lewy bodies Multiple system atrophy
Cholinesterase inhibitors (ChE-Is) Donepezil (Aricept) Rivastigmine (Exelon) Galantamine (Razadyne) NMDA receptor antagonist Memantine (Namenda)
Symptomatic effects Mild improvement and delay of decline Cognition Function (activities of daily living) Behavior Global measures
Many patients are treated (off label) with psychotropic agents Antidepressants Atypical antipsychotics Care of the caregiver is an important aspect of patient management
Side effects Cholinesterase inhibitors Diarrhea Nausea, vomiting Memantine Headache Dizziness Somnolence
DementiaTreatment Parkinson’s diseaseRivastigmine (FDA approved); psychotropics Vascular dementiaChE-Is (off label); psychotropics; control risk factors (hypertension, cholesterol) Dementia with Lewy bodiesChE-Is (0ff label); psychotropics Frontotemporal dementiaMemantine (off label); psychotropics
Dementias are preceded by states of mild cognitive impairment Memory impairment without functional loss Not all MCI progresses to dementia Some are stable in MCI state Some improve Some progress to AD (60% of MCI) Some progress to non-AD dementias
Memory impairment Progressive Not attributable to another cause (e.g., hypothyrodism) Biomarker evidence of AD as the cause of the “MCI” Medial temporal atrophy on MRI Parietal hypometabolism on FDG PET (bilateral) Positive amyloid imaging CSF with low amyloid and high tau/p-tau levels
MCI Normal
FDG PET Shows Reduced Brain Metabolism in the Parietal Lobes
Klunk WE, et al. Ann Neurol. 2004;55: PIB = Pittsburgh Compound B; amyloid imaging
Anti-amyloid therapies Gamma secretase inhibitors (decrease production) Aggregation inhibitors (prevent toxicity) Immunotherapies (passive; vaccination)(remove deposits) Tau-related therapies Neuroprotective agents Latreperdine/dimebon Anti-oxidants
Amyloid Precursor Protein Aggregated Aß Neurofibrillary tangles, mitochondrial dysfunction, oxidation, synaptic dysfunction, neuronal loss New Therapies Address the Neurobiology of AD
Amyloid Precursor Protein Aggregated Aß Neurofibrillary tangles, mitochondrial dysfunction, oxidation, synaptic dysfunction, neuronal loss Aß Aggregation: Aß Removal Mitochondrial Function; Oxidation; Inflammation; Neuroprotection Aß Production New Therapies Address the Neurobiology of AD
Dementia is common among the elderly and growing in frequency Dementia requires memory loss, loss in another cognitive domain and functional impairment Dementia has many causes Alzheimer’s disease is the most common cause of dementia AD is treated with cholinesterase inhibitors and memantine